| CYPRIUM-THERAPEUTICS-INC |
CYPRIUM-THERAPEUTICS-INC |
92%
|
Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher |
| DERM |
Journey Medical Corporation |
90%
|
Reciprocal relationship from DERM graph: Reciprocal relationship from FBIO graph: The Amendment amended the financial covenant requiring that product net sales of Journey Medical Corporation, a contr… |
| DERM |
Journey Medical Corporation |
90%
|
The Amendment amended the financial covenant requiring that product net sales of Journey Medical Corporation, a controlled subsidiary of the Company, meet a consolidated minimum net sales amount |
| CRYSTALYS-THERAPEUTICS-INC |
CRYSTALYS-THERAPEUTICS-INC |
80%
|
Urica sold the rights to its dotinurad program and related intellectual property to Crystalys |
| CUTIA-THERAPEUTICS-HK-LIMITED |
CUTIA-THERAPEUTICS-HK-LIMITED |
80%
|
Journey supplies finished product and earns low single-digit royalties on net sales to Cutia Therapeutics (HK) Limited |
| ATXI |
Avenue Therapeutics, Inc. |
72%
|
Reciprocal relationship from ATXI graph: Reciprocal relationship from FBIO graph: Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Se… |
| ATXI |
Avenue Therapeutics, Inc. |
72%
|
Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axsome”), and Sun Pharma. Our subsidiaries an… |
| AXSM |
Axsome Therapeutics, Inc. |
72%
|
Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axsome”), and Sun Pharma. Our subsidiaries an… |
| AXSM |
Axsome Therapeutics, Inc. |
72%
|
Reciprocal relationship from AXSM graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from AXSM g… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FBIO graph: ecognize additional shares received p… |
| LLY |
Eli Lilly and Company |
72%
|
ecognize additional shares received pursuant to its anti-dilution rights under the APA, resulting in an increase in estimated fair value of $ 15.1 million which was recorded as other income in the Co… |
| MBIO |
Mustang Bio, Inc. |
72%
|
Reciprocal relationship from MBIO graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from MBIO graph: Reciprocal relationship from FBIO graph: Zeneca plc as successor-in-interest… |
| MBIO |
Mustang Bio, Inc. |
72%
|
Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axsome”), and Sun Pharma. Our subsidiaries an… |
| TGTX |
TG Therapeutics, Inc. |
72%
|
r ended December 31, 2029 3,054 Year ended December 31, 2030 3,056 Other 2,058 Total operating lease liabilities 16,780 Less: present value discount ( 2,531 ) Net operating lease liabil… |
| TGTX |
TG Therapeutics, Inc. |
72%
|
Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIO graph: r ended December 31, 2029 3,054… |
| XYF |
X Financial |
72%
|
. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the Consolidated Balance Sheet as both a right-of-use asset a… |
| XYF |
X Financial |
72%
|
Reciprocal relationship from XYF graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from XYF graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from XYF grap… |
| ABBVIE-BIORESEARCH-CENTER-INC |
ABBVIE-BIORESEARCH-CENTER-INC |
62%
|
gonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy. Avenue intends to advance ATX-04 through a late-stage clinical deve… |
| ALEXION-PHARMACEUTICALS-INC |
ALEXION-PHARMACEUTICALS-INC |
62%
|
ddition, the Company shall pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future mile… |
| ANNJI-PHARMACEUTICAL-CO-LTD |
ANNJI-PHARMACEUTICAL-CO-LTD |
62%
|
echnological feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts… |
| ARMISTICE-CAPITAL-MASTER-FUND-LTD |
ARMISTICE-CAPITAL-MASTER-FUND-LTD |
62%
|
Merger Agreement and established May 28, 2025 as the date for a special meeting of Checkpoint stockholders to vote on the Merger. Following the approval of the Merger by requisite majorities of holde… |
| BOSTON-BIOSCIENCES-INC |
BOSTON-BIOSCIENCES-INC |
62%
|
al repayments commencing in February 2027 rather than February 2026. Thereafter, Journey will make quarterly principal payments equal to $ 2.5 million per quarter, or 10.0 %, of the outstanding princ… |
| CAELUM-BIOSCIENCES-INC |
CAELUM-BIOSCIENCES-INC |
62%
|
ddition, the Company shall pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future mile… |
| CAELUM-BIOSCIENCES-INC-CAELUM-BIOSCIENCES-INC |
CAELUM-BIOSCIENCES-INC-CAELUM-BIOSCIENCES-INC |
62%
|
ddition, the Company shall pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future mile… |
| CARIBE-BIOADVISORS-LLC |
CARIBE-BIOADVISORS-LLC |
62%
|
r ended December 31, 2029 3,054 Year ended December 31, 2030 3,056 Other 2,058 Total operating lease liabilities 16,780 Less: present value discount ( 2,531 ) Net operating lease liabil… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
. The notes, analyses and memoranda that we have generated based on such information are also valuable to our businesses, and the unauthorized disclosure or misappropriation of such materials by our … |
| HK-LIMITED |
HK-LIMITED |
62%
|
echnological feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts… |
| INVAGEN-PHARMACEUTICALS-INC |
INVAGEN-PHARMACEUTICALS-INC |
62%
|
se agreement between Avenue and InvaGen Pharmaceuticals, Inc. (“InvaGen”) under which Avenue repurchased all of InvaGen’s shares in Avenue, Avenue agreed to pay InvaGen an additional amount as a cont… |
| LABORATORIES-LTD |
LABORATORIES-LTD |
62%
|
ecognize additional shares received pursuant to its anti-dilution rights under the APA, resulting in an increase in estimated fair value of $ 15.1 million which was recorded as other income in the Co… |
| LUPIN-LIMITED-LUPIN-INC |
LUPIN-LIMITED-LUPIN-INC |
62%
|
rity to perform studies in addition to those currently expected; ● there are any delays in completing our clinical trials or the development of any of our product candidates; ● we execute other colla… |
